Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the American Liver Foundation. Until now, the only FDA-approved treatment for the condition was Madrigal Pharmaceuticals’ Rezdiffra, cleared in 2024.